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Hypertensive mice that express the human renin and angiotensinogen genes are used as a model for human hypertension because
theydevelophypertensionsecondarytoincreasedrenin-angiotensinsystemactivity.Ourstudyinvestigatedthecellularlocalization
and distribution of COX-1, COX-2, mPGES-1, and mPGES-2 in organ tissues from a mouse model of human hypertension. Male
(n = 15)andfemale(n = 15)doubletransgenicmice(h-Ang204/1h-Ren9)wereusedinthestudy.Lung,kidney,andhearttissues
were obtained from mice at necropsy and ﬁxed in 10% neutral buﬀered formalin followed by embedding in paraﬃnw a x .C u t
sections were stained immunohistochemically with antibodies to COX-1, COX-2, mPGES-1, and mPGES-2 and analyzed by light
microscopy. Renal expression of COX-1 was the highest in the distal convoluted tubules, cortical collecting ducts, and medullary
collecting ducts; while proximal convoluted tubules lacked COX-1 expression. Bronchial and bronchiolar epithelial cells, alveolar
macrophages, and cardiac vascular endothelial cells also had strong COX-1 expression, with other renal, pulmonary, or cardiac
microanatomic locations having mild-to-moderate expression. mPGES-2 expression was strong in the bronchial and bronchiolar
epithelial cells, mild to moderate in various renal microanatomic locations, and absent in cardiac tissues. COX-2 expression was
strongin theproximal anddistal convoluted tubules,alveolar macrophages, and bronchial and bronchiolar epithelial cells. Marked
mPGES-1 was present only in bronchial and bronchiolar epithelial cells; while mild-to-moderate expression was present in other
pulmonary, renal, or cardiac microanatomic locations. Expression of these molecules was similar between males and females. Our
work suggests that in hypertensive mice, there are (a) signiﬁcant microanatomic variations in the pulmonary, renal, and cardiac
distribution and cellular localization of COX-1, COX-2, mPGES-1, and mPGES-2, and (b) no diﬀerences in expression between
genders.
Copyright © 2007 Z. A. Radi and R. Ostroski. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
The renin-angiotensin-aldosterone system (RAAS) plays an
important role in the control of cardiovascular and re-
nal homeostasis by regulating vascular tone, blood pressure
(BP), and ﬂuid volume [1, 2]. Angiotensin II (Ang II) is
a physiologically active component of the RAAS, produced
via an enzymatic cascade that begins with angiotensinogen
(AGT) cleaving renin (REN) to form angiotensin I (Ang I),
which is then cleaved by the angiotensin converting enzyme
(ACE) to form Ang II [3]. Ang II causes vasoconstriction di-
rectly by activating Ang II type 1 (AT1) receptors on vascular
smooth muscle, aﬀects ﬂuid volume via AT1 receptor acti-
vation in the proximal tubule, resulting in renal sodium and
water reabsorption, and plays an important role in the reg-
ulation of ﬂuid balance by stimulating aldosterone secretion
fromthezonaglomerulozaoftheadrenalglands[3].ACEin-
hibitors, Ang II receptor antagonists, and aldosterone recep-
tor antagonists have been used as therapeutic interventions
to treat hypertension.
The genes of the renin-angiotensin have been linked
to and/or associated with hypertension in animal models
and humans [2]. Recently, transgenic rodent models have
been developed that over express both human REN and an-
giotensinogen, which leads to hypertension via chronic over-
production of Ang II. Speciﬁc examples include the murine2 Mediators of Inﬂammation
double transgenic line (Ang 204/1 Ren 9), which produces
a mean arterial BP 40mmHg higher than background mice
(C57Bl/6J) that lack the human genes [2]. These mice also
had elevated aldosterone levels. In addition, transgenic rats
harboring the mouse renin-2 gene developed hypertension,
cardiac hypertrophy, and renal damage [4]. The Tsukuba hy-
pertensive mice (THM), which express the human REN and
angiotensinogen genes, have been proven to develop hyper-
tension [5].
Originally, the RAAS was viewed solely as an endocrine
system, in which angiotensinogen of hepatic origin is se-
creted intothe systemic circulation and cleaved by REN and
ACE to produce the active peptide Ang II. However, there is
increasing evidence that suggests a RAAS may reside within
several organs or tissues, including kidney, lung, heart, and
vascular smoothmuscle cells (SMC), where it is believed to
act in a functionally independent paracrine/autocrine fash-
ion [6]. This hypothesis is further supported by the fact that
all components of the RAAS in the heart, kidney, and lung
contain the ACE component [3, 6]. Additionally, high con-
centrations of Ang II have been demonstrated in the plasma,
heart, and kidney of THM [7, 8].
In the kidney, prostaglandins (PGs) are important me-
diators of hemodynamic regulation, salt and water home-
ostasis, and REN release [9, 10]. The main PG in the kidney
is PGE2, which is synthesized from arachidonic acid (AA)
by enzymatic reactions, particularly cyclooxygenases and
prostaglandin E synthases (PGES). Cyclooxygenase (COX)
derived PGs have two distinct membrane-anchored isoen-
zymes,COX-1andCOX-2.COX-1isconstitutivelyexpressed
and found in most normal body tissues, while COX-2 is
expressed in normal tissues at low levels and is highly in-
duced by proinﬂammatory mediators in inﬂammation, in-
jury, and pain settings [9]. The membrane-associated PGES-
1 (mPGES-1) is inducible and functionally linked to COX-2,
whilemPGES-2is constitutive andcoupledto both COX iso-
forms [11].
IthasbeensuggestedthatregulationofCOX-2inthekid-
ney is altered by the RAAS system [9, 12]. In THM mice, in-
creased expression of COX-2 in the macula densa has been
reported [13], and an important role for RAAS in cardiac
hypertrophy has been noted [14]. In addition, activation
of RAAS has been demonstrated in rats with heart failure
[6]. Overexpression of COX-2 has also been observed in the
aldosterone-treated animals in normotensive and hyperten-
sive rats [15].
In the lung, signiﬁcant reduction in BP was seen in PG
EP1 receptor-deﬁcient mice and was accompanied by in-
creased REN-Ang activity [16]. In addition, plasma Ang II
levels were raised in severe asthma [17].
There are currently no published reports on the cellu-
lar expression and microanatomic location of COX-1, COX-
2, mPGES-1, mPGES-2 in hypertensive transgenic mice.
Therefore, using immunohistochemistry, we investigated the
microanatomic location and cellular expression of COX-1,
COX-2, mPGES-1, mPGES-2 in kidney, lung, and heart tis-
sues obtained from renin-angiotensingen transgenic mice.
This study is the ﬁrst to report on the pulmonary and Car-
diorenalmicroanatomicexpressionofthesemoleculesinthis
animal model for human hypertension.
2. MATERIALS AND METHODS
2.1. Animals
15- to 20-week-old male (n = 15) and female (n = 15) dou-
ble transgenic mice (h-Ang 204/1 h-Ren 9) were used in the
study. The mice were derived from a founder colony of 5
malemiceexpressinghumanangiotensinogen(h-Ang204/1)
and 6 females expressing human renin (h-Ren6), obtained
from Dr. Curt Sigmund at the University of Iowa, School of
Medicine. At Charles River Laboratories (Wilmington, Mas-
sachusetts), female mice that expressed human REN were
bred with angiotensinogen-expressing males to produce the
double transgenic line. The transgenic line was developed on
a C57/BI6J background. All the procedures were in compli-
ance with the Pﬁzer Ann Arbor Laboratories Animal Care
and Use Committee.
2.2. Studytissuesamples
Lung, kidney, and heart tissues were obtained from the mice
at the time of necropsy. Tissues were ﬁxed in 10% neutral
buﬀered formalin for 24 hours and embedded in paraﬃn
wax. 3µm-thick sections were then cut and stained immuno-
histochemically with antibodies to COX-1, COX-2, mPGES-
1, and mPGES-2.
2.3. ImmunohistochemistryforCOX-1,COX-2,
mPGES-1,andmPGES-2
To analyze the expression of COX-1, COX-2, mPGES-1,
and mPGES-2, 3µm sections were cut from formalin-ﬁxed,
paraﬃn-embedded blocks, mounted on positively charged
glass slides, dried, and then loaded on the automated im-
munostainer (room temperature using a Ventana Discovery
(VentanaMedicalSystems,Tucson,AZ).Slidesweredeparaf-
ﬁnized and then rehydrated. Sections were incubated for 30
m i n u t e sw i t hs e r u mf r e eD a k o C y t o m a t i o np r o t e i nb l o c k e r
(Dako Corporation, Dako, CA) and then rinsed and incu-
bated for 4 minutes with Avidin-Biotin blocking solution
(Ventana Medical Systems). Antigen retrieval was completed
with a Ventana specialty solution (8 = pH) (Ventana Medical
Systems).
Automation included exposure to 100µLo fp r i m a r y
anti-COX-1 (1:200), COX-2 (1:20), mPGES-1 (1:750), or
mPGES-2(1:1000)antibody(CaymanChemical,AnnArbor,
MI) diluted with reagent diluent (Ventana Medical Systems)
at room temperature for 60 minutes. 100µL of the appropri-
ate anti-rabbit biotinylated IgG linking solution (Vector Lab-
oratories) was applied to each section at 1:200 dilution for
60 minutes at room temperature. Sections were again rinsed
and allowed to react with 100µL of diaminobenzidine (DAB
detection kit) substrate solution (Ventana Medical Systems)
for8minutes,followedbycounterstainingwithHematoxylin
and then Bluing Reagent for 4 minutes each, removed fromZ. A. Radi and R. Ostroski 3
(a) COX-1 expression in the kidney from a hy-
pertensive mouse. Strong expression in the distal
convolutedtubulesandcortical-collectingducts
(long arrows). Note the lack of expression in
theproximalconvolutedtubules(shortarrows).
Immunohistochemical stain, original magniﬁ-
cation X10.
(b) COX-1 expression in the lung from a hyper-
tensive mouse. Strongexpressioninthebronchi-
olar epithelial cells (long arrows). Immunohis-
tochemical stain, original magniﬁcation X10.
Figure 1
the autostainer, washed in warm water, dehydrated through
graded alcohol, cleared in xylene, and cover slipped. Control
reactions included (1) sections incubated with the omission
of primary antibody and processed as mentioned above, and
(2) sections incubated with normal rabbit serum instead of
the primary antibody and processed as above.
3. RESULTS
The pulmonary and Cardiorenal cellular expression and dis-
tribution of COX-1, COX-2, mPGES-1, and mPGES-2 are
summarizedinTables1,2,3,and4.Stainingintensityranged
from negative (−) to strong (+++).
In the kidney, strong diﬀuse cytoplasmic COX-1 expres-
sion occurred in the distal convoluted tubules (DCT), cor-
tical collecting ducts, and medullary collecting ducts, while
proximal convoluted tubules (PCT) lacked COX-1 expres-
sion (see Figure 1(a) and Table 1). Moderate (++) diﬀuse
COX-1 cytoplasmic staining was present in vascular en-
dothelial cells (EC) and SMC, cortical interstitial cells (IC),
the glomerular visceral epithelium, and the capsular pari-
etal epithelium. Mild (+) COX-1 expression was present in
medullary IC, glomerular podocytes, and the medullary as-
cending limb (MAL). Expression of COX-1 was equivocal in
the macula densa.
In the lungs and heart, COX-1 was strongly expressed in
alveolar macrophages, the bronchial and bronchiolar epithe-
lium, and cardiac vascular endothelial cells, but moderately
expressed in alveolar septa, bronchial smooth muscle cells,
pulmonary vascular endothelial cells, pulmonary vascular
EC, and cardiac vascular SMC. COX-1 was not expressed in
cardiac myocytes (see Figure 1(b) and Table 2).
mPGES-2 was expressed in the kidney at a moderate dif-
fuse level in PCT and DCT, capsular parietal epithelium,
and medullary collecting ducts (see Figure 2(a) and Table 1).
Mild expression was present in macula densa, vascular SMC
Table 1: Renal immunohistochemical expression of mPGES-2 and
COX-1. PCT = proximal convoluted tubules; DCT = distal convo-
luted tubules; SMC = smooth muscle cells; EC = endothelial cells;
IC = interstitial cells; MAL = medullary ascending limb.
Cellular location mPGES-2 COX-1
Macula densa + ±
PCT ++ −
DCT ++ +++
Vascular SMC + ++
Vascular EC + ++
Cortical IC − ++
Medullary IC − +
Glomeruli (podocytes) + +
Glomerular (visceral) epithelium + ++
Capsular (parietal) epithelium ++ ++
Cortical collecting ducts + +++
Medullary collecting ducts ++ +++
MAL + +
(±) = equivocal staining; (−) = no staining, (+) = mild staining;
(++) = moderate staining; (+++) = strong staining.
and EC, glomerular podocytes and the visceral epithelium,
cortical collecting ducts, and the MAL. No mPGES-2 expres-
sion was present in cortical or medullary IC.
Pulmonary expression of mPGES-2 included strong dif-
fuse staining in bronchial and bronchiolar epithelial cells
(see Figure 2(b) and Table 2), moderate staining in alveolar
macrophagesandsepta,mildstaininginbronchialSMC,and
pulmonary vascular EC and SMC. No mPGES-2 expression
was present in any of the cardiac microanatomic locations
examined.
Renal COX-2 expression was strong in the PCT and DCT
(seeFigure 3(a)andTable 3),moderateinmaculadensa,vas-
cular SMC and EC, and medullary collecting ducts, and mild4 Mediators of Inﬂammation
(a) mPGES-2 expression in the kidney from a
hypertensive mouse. Moderate expression in the
proximal and distal convoluted tubules (long
arrows). Immunohistochemical stain, original
magniﬁcation X10.
(b) mPGES-2 expression in the lung from a hy-
pertensivemouse.Strongexpressioninthebron-
chiolar epithelial cells (long arrows). Immuno-
histochemicalstain,originalmagniﬁcationX10.
Figure 2
Table 2: Pulmonary and cardiac immunohistochemical expression
of mPGES-2 and COX-1. SMC = smooth muscle cells; EC = en-
dothelial cells.
Cellular location mPGES-2 COX-1
Alveolar macrophages ++ +++
Alveolar septa ++ ++
Bronchial epithelium +++ +++
Bronchial SMC + ++
Bronchiolar epithelium +++ +++
Pulmonary vascular EC + ++
Pulmonary vascular SMC + ++
Cardiac myocytes −−
Cardiac vascular SMC − ++
Cardiac vascular EC − +++
(−) = no staining; (+) = mild staining; (++) = moderate staining;
(+++) = strong staining.
in cortical and medullary interstitial cells, cortical collecting
ducts, and the MAL. No expression was present in glomeruli
or the capsular (parietal) epithelium.
In the lung, marked (+++) COX-2 expression was
present in alveolar macrophages, and the bronchial and
bronchiolar epithelium (see Figure 3(b) and Table 4). Other
pulmonary microanatomic locations had mild or equivocal
COX-2 expression. Cardiac vascular EC had mild COX-2 ex-
pression, while cardiac myocytes and cardiac vascular SMC
were negative.
For mPGES-1, expression was mild in renal vascular
SMC and EC, cortical and medullary collecting ducts, and
the MAL (see Figure 4(a) and Table 3). Expression in the
maculadensa,glomerular(visceral)epithelium,andcapsular
(parietal)epitheliumwasequivocal.NomPGES-1expression
was present in other microanatomic renal locations.
mPGES-1 was the highest in bronchial and bronchiolar
epithelial cells (see Figure 4(b) and Table 4). Moderate ex-
pression was present in bronchial SMC. Mild expression was
present in alveolar macrophages and alveolar septa, while ex-
pression in pulmonary vascular EC and SMC was equivo-
cal. Mild mPGES-1 expression was present in cardiac vascu-
lar EC and cardiac vascular SMC, while other cardiac mi-
croanatomic locations lacked expression. The expression of
all these molecules was similar between males and females.
4. DISCUSSION
PGs are modulators of physiological functions and con-
tribute to REN release, regulation of renal microvascular
hemodynamics, salt balance, and BP controlvia mechanisms
involving the regulation of vascular tone and renal excre-
tory function. The kidney is capable of synthesizing all types
of PGs, especially PGE2 and PGI2, which inﬂuence urinary
sodium excretion directly through inhibition of the tubular-
transport function and indirectly through the regulation of
renin-angiotensin system activity [18]. COX, a rate-limiting
enzyme in the PG biosynthesispathway, exists in two major
isoforms: the constitutive COX-1 and the inducible COX-2
[19]. COX-1 is expressed constitutively at varying levels in
the majority of tissues and generally plays a role in tissue
homeostasis.
In this study, the highest degree of renal COX-1 ex-
pression occurred in the DCT, cortical collecting ducts, and
medullary collecting ducts, while mild-to-moderate COX-1
expression occurred in other microanatomic renal locations.
PCT lacked COX-1 expression. These results are concurrent
with COX-1 being the most abundant COX isoform that is
constitutively expressed in the kidney and regionally local-
ized in the renal vasculature, collecting ducts, and papillary
IC across various species [20, 21]. Further evidence support-
ing these results includes previous work in which various
species (cow, dog, guinea pig, human, monkey, mouse, rab-
bit,rat,andsheep)exhibitedhighlevelsofCOX-1expression
in the collecting ducts [20, 22, 23].Z. A. Radi and R. Ostroski 5
(a) COX-2expressioninthekidneyfromahyper-
tensivemouse.Strongexpressionintheproximal
and distal convoluted tubules (long arrows).
Immunohistochemical stain, original magniﬁ-
cation X10.
(b) COX-2 expression in the lung from a hyper-
tensive mouse. Strongexpressioninthebronchi-
olar epithelial cells (long arrows). Immunohis-
tochemical stain, original magniﬁcation X10.
Figure 3
Table 3: Renal immunohistochemical expression of mPGES-1 and
COX-2. PCT = proximal convoluted tubules; DCT = distal convo-
luted tubules; SMC = smooth muscle cells; EC = endothelial cells;
IC = interstitial cells; MAL = medullary ascending limb.
Cellular location mPGES-1 COX-2
Macula densa ± ++
PCT − +++
DCT − +++
Vascular SMC + ++
Vascular EC + ++
Cortical IC − +
Medullary IC − +
Glomeruli (podocytes) −−
Glomerular (visceral) epithelium ±−
Capsular (parietal) epithelium ±−
Cortical collecting ducts + +
Medullary collecting ducts + ++
MAL + +
(±) = equivocal staining; (−) = no staining; (+) = mild staining;
(++) = moderate staining; (+++) = strong staining.
Since COX-1 is expressed in the collecting ducts of the
nephron, an active area in the regulation of sodium ex-
cretion in both laboratory animals and humans [24], it is
not surprising that BP increases in COX-1 deﬁcient mice
compared with wild-type controls [25]. Nonselective non-
steroidal anti-inﬂammatory drugs (NSAIDs) may aggravate
renin-independent, sodium-sensitive hypertension, possibly
in part by inhibition of the COX-1 responsible for sodium
excretion [26]. In rats infused with selective COX inhibitors,
NS-398 or meloxicam, direct renal interstitial volume expan-
sion signiﬁcantly increased renal interstitial hydrostatic pres-
sure and fractional excretion of sodium [27].
Our ﬁnding that most cardiac microanatomic locations
had COX-1 expression with the exception of cardiac my-
ocytes is consistent with other studies showing COX-1 ex-
pression in both EC and SMC of the fetal ductus arterio-
sus of pigs, rats, sheep, and humans [28–31]. Furthermore,
COX-1 was constitutively expressed in the EC of the aorta
and microvasculature,ﬁbrous connective tissue of the tricus-
pid valve, and chordae tendinae of the heart of dog [32].
All pulmonary microanatomic locations had COX-1 ex-
pression in our study. Other examples of COX-1 expres-
sion in lungs include human lungs [33], and the bronchiolar
epithelium and smooth muscle, alveolar macrophages, EC,
and vascular SMC of rat [34]. As a result, COX-1-dependent
prostanoid generation has been implicated in the regulation
of bronchial tone [34].
mPGES-2 is constitutively expressed in several tissues,
is not induced during inﬂammation, and has been pro-
posed to mediate PGE2 production from both COX isoforms
[11, 35]. In our study, moderate mPGES-2 expression was
present in PCT and DCT, the capsular parietal epithelium,
and medullary collecting ducts, while mild or no expres-
sion was present in other renal microanatomic locations. In
otherstudies,highexpressionofmPGESwasreportedindis-
tal tubules, and medullary collecting ducts in normal mouse
kidney [36]. mPGES-2 was expressed in all pulmonary mi-
crostructures examined.
In the heart, mPGES-2 was not present in any mi-
croanatomic locations. Other studies using primary cultures
of neonatal ventricular myocytes have shown that mPGES-2
is constitutively synthesized in myocytes and is not regulated
[37].
COX-2 is expressed in variable locations in the kidney
across various species [20]. COX-2 deﬁcient mice exhibited
severe disruption of renal development and function, sug-
gesting an important role for COX-2 in renal development
[38, 39]. The normal rodent and canine kidney have promi-
nent constitutive COX-2 expression in the macula densa
and thick ascending limb of loop of Henle, whereas COX-
2 is absent at these sites in the normal primate and hu-
man kidney [21]. In our study, COX-2 was present in all
microanatomic renal locations, with the exception of the6 Mediators of Inﬂammation
(a) mPGES-1 expression in the kidney from
ah y p e r t e n s i v em o u s e .Mild expression in the
cortical-collecting ducts (long arrows). Im-
munohistochemical stain, original magniﬁca-
tion X10.
(b) mPGES-1 expression in the lung from a hy-
pertensivemouse.Strongexpressioninthebron-
chiolar epithelial cells (long arrows). Immuno-
histochemicalstain,originalmagniﬁcationX10.
Figure 4
Table 4: Pulmonary and cardiac immunohistochemical expression
of mPGES-1 and COX-2. EC = endothelial cells; SMC = smooth
muscle cells.
Cellular location mPGES-1 COX-2
Alveolar macrophages + +++
Alveolar septa + +
Bronchial epithelium +++ +++
Bronchial SMC ++ +
Bronchiolar epithelium +++ +++
Pulmonary vascular EC ± +
Pulmonary vascular SMC ±±
Cardiac myocytes −−
Cardiac vascular SMC + −
Cardiac vascular EC + +
(±) = equivocal staining; (−) = no staining; (+) = mild staining;
(++) = moderate staining; (+++) = strong staining.
glomeruli and capsular (parietal) epithelium. This ﬁnding
is consistent with the known regulatory association between
COX-2 and REN reported by Schnermann [40]. Demonstra-
tion that indomethacin and SC58236 (a selective COX-2 in-
hibitor)candecreaseBPandsuppressplasmaRENactivityin
rats lends further support to this association [41, 42]. Con-
versely,COX-2knockoutmicehadreducedRENcontentand
activity [43].
The marked increase of COX-2 expression in the pul-
monaryepitheliuminourstudyisconsistentwiththeknown
role of respiratory epithelia as a ﬁrst line of defense. Pul-
monary epithelial cells have an important role in airway
homeostasis, perform many important biological functions,
and represent the ﬁrst line of defense against infection [44].
Activation of the renin-angiotensin system has also been
demonstrated in acute asthma [17].
Cardiac vascular EC and SMC had COX-2 expression,
while no expression was present in cardiac myocytes or SMC
in our study. Ang II is known to stimulate vascular SMC
growth [45]. An important role for Ang II in the regulation
of COX-2 has been reported [46].
mPGES-1 is a source of inducible PGE2 synthetic activity
[47]. In this study, mPGES-1 was present in renal vascular
EC and SMC, cortical and medullary collecting ducts, MAL,
all pulmonary microanatomic locations, and cardiac vascu-
lar EC and SMC, while no expression was present in other
renal or cardiac microanatomic locations. These ﬁndings are
consistentwithincreasedmPGESexpressiondescribedinpa-
tients with hyperprostaglandin E syndrome [48]. mPGES-1
was also induced by the proinﬂammatory cytokine in cardiac
myocytes and ﬁbroblasts [37].
In conclusion, in hypertensive mice there are (a) signiﬁ-
cant microanatomic variations in the pulmonary, renal, and
cardiac distribution and cellular localization of mPGES-1,
mPGES-2, COX-1, and COX-2 and (b) no diﬀerences in ex-
pression between genders.
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